TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients

Abstract

Background

Tumor necrosis factor (TNF)-α and -β are cytokines with a wide range of inflammatory, apoptotic and immunomodulatory activities. TNF-α promoter –308 G < A polymorphism has been reported to be associated with rheumatoid arthritis (RA) with inconsistent results.

Objective

The aim of this study is to elucidate a possible association of TNF-α (G–308A) and TNF-β (A+252G) polymorphisms with the susceptibility of RA in Saudi patients.

Patients and Methods

This case control study consisted of 232 Saudi subjects including 106 RA patients and 126 matched controls. Genomic DNA was extracted using QIAamp^R DNA mini kit (Qiagen CA, USA). TNF-α and TNF-β genes were amplified using Arms primers.

Results

The frequencies of TNF-α (–308) allele G and genotype GG were significantly higher in RA patients as compared to controls while allele A and genotype AA were predominant in control group. On the other hand the frequency of TNF-β (+252) GG and AA genotypes were significantly higher in RA patients as compared to controls while GA genotype was predominant in controls. It was inferred that genotype GG positive individuals at position –308 of TNF-α were susceptible to RA while genotype AA might has a protective effect on RA susceptibility in Saudis. Whereas GG and AA genotype of TNF-β at +252 position might exert additive susceptibility to RA and GA might be refractory. However, there was no significant association between duration of morning stiffness, RF positivity and number of joints involved and distribution of alleles/genotypes of TNF-α (–308) or TNF-β (+252) polymorphism. It may be concluded that the TNF-α (–308) and TNF-β (+252) polymorphisms might influence the susceptibility to RA in Saudi population. These results might have prognostic value for future clinical observations.

Keywords

tumor necrosis factor rheumatoid arthritis polymorphism Saudi

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting 0.5 to 2% of the world's population. Abundant expression of pro- and anti-inflammatory cytokines observed in the affected tissues and serum of RA patients clearly indicates the involvement of cytokines in the etiopathology of RA.¹ Tumor necrosis factor (TNF), a pro-inflammatory cytokine has been shown to play a pivotal role in the pathogenesis of several autoimmune diseases including RA.^1–3 This is further evident from significantly high levels of TNF in the synovial fluid of RA patients.

TNF-α and TNF-β are closely related cytokines that share 30% amino acid residues and use the same cell surface receptor.⁴ Nedwin et al⁵ reported that the TNF-α and TNF-β genes are located in tandem on chromosome 6 between the Class I and Class II cluster of the major histocompatibility complex (chromosome 6p21.1–6p21.3). Among the five polymorphisms (at position +691,–238, –308, –851, and –857) of TNFα gene identified by PCR-SSCP analysis, TNFα –308 polymorphism has been reported to be associated with several autoimmune diseases including RA.^6,7 The genetic variation on position –308 results in two allelic forms in which the presence of guanine (G) defines the common variant and the presence of adenine (A) defines the less common one. TNFα-308A-allele displays increased gene transcription as compared to the common allele G.⁸ It has been shown to produce 6–7 fold higher levels of TNF-α transcription.^8,9

Tumor necrosis factor β (TNF-β) which is closely linked to TNF-α, has also been shown to contribute to the susceptibility of several autoimmune diseases.^10,11 A polymorphism has been reported at position +252 within the first intron of the TNF-β gene, consisting of a Guanine (TNF-β +252G) on one allele and an Adenine (TNF-β +252A) on the alternate allele.¹² The presence of G at this position defines the mutant allele known as TNF-β * 1 (allele-1) which is less frequent allele in white subjects and is associated with higher TNF-α and TNF–β production.^12,13 Recently a study on Japanese population has shown that TNFβ (+252) polymorphism together with HLA-DRB1*0405 influences the susceptibility to RA.¹⁴

Overall the data related to allele and genotype distribution of TNF-α and TNF-β polymorphisms in RA patients from various populations is limited and inconclusive. In this study an attempt was made to determine a possible association of TNF-α (G–308A) and TNF-β (A+252G) polymorphism with RA in Saudi population.

Materials and Methods

Patients and Controls

A total of 232 subjects visiting Armed Forces Hospital, Riyadh, Saudi Arabia were recruited (during 2007–2008) for this study. The diagnosis of RA was made according to the revised criteria of American College of Rheumatology.¹⁵ RA group consisted of 106 unrelated Saudi RA patients [male = 21, female = 85, age range 26 to 75 years (mean age 49 ± 12.5 years)]. The control group consisted of 126 matched, unrelated healthy blood donors [male = 50, female = 76, age range 25 to 70 years (mean age 48 ± 11.5 years)] from the same Saudi population.

PCR Amplification

Genomic DNA was extracted from the peripheral blood of RA patients and controls using QIAamp^R DNA mini kit (Qiagen CA, USA). TNF-α and TNF-β genes were amplified using amplification refractory mutation systems (ARMS)-PCR methodology¹⁶ to detect any polymorphism involved at position –308 of TNF-α and position +252 in Interon1 of TNF-β gene respectively. The set of primers used to amplify target DNA in the promoter region of TNF-α and TNF-β genes are summarized in Table 1. PCR amplification was carried out using Ready to Go PCR Beads (Amersham Biosciences, USA). Reaction consisted of 10 temperature cycles of denaturation for 15 s at 94 °C, annealing for 50 s at 65 °C and extension for 40 s at 72 °C. Then 25 cycles of denaturation for 20 s at 94 °C, annealing for 50 s at 59 °C and extension for 50 s at 72 °C. Final extension was performed at 72 °C for 7 min. A positive control was included in the PCR assay by amplification of the human growth hormone (HGH) gene. The amplified product for various samples were separated on the 1.5% agarose gel, stained with ethidium bromide and photographed.

Table 1.

Showing sets of sense and antisense primers used to amplify the TNF-α and TNF-β to detect polymorphism.

Locus	Generic (antisense) primer	Sense primers
TNFα (G-308A)	5'-TCT CGG TTT CTT CTC CAT CG-3'	5'-ATA GGT TTT GAG GGG CAT GG-3'
TNFα (G-308A)	5'-TCT CGG TTT CTT CTC CAT CG-3'	5'-AAT AGG TTT TGA GGG GCA TGA-3'
TNFβ (interon1 ± 252)	5'-AGA TCG ACA GAG AAG GGG ACA 3'	5'-CAT TCT CTG TTT CTG CCA TGG-3'
TNFβ (interon1 ± 252)	5'-AGA TCG ACA GAG AAG GGG ACA 3'	5'-CAT TCT CTG TTT CTG CCA TGA-3'

Statistical Analysis

The differences in allele/genotype frequencies between patients and controls were analyzed by the Fisher's exact test. P values less than 0.05 were considered significant. The strength of the association of disease with respect to a particular allele/genotype is expressed by odd ratio interpreted as relative risk (RR) following the Woolf's method as out lined by Schallreuter et al.¹⁷ It was calculated only for those alleles/genotypes which were increased or decreased in arthritis patients as compared to control group. The RR was calculated for all the subjects using the formula given below:

RR = (a) \times (d) / (b) \times (c)

a = number of patients with expression of allele or genotype

b = number of patients without expression of allele or genotype

c = number of controls with expression of allele or genotype

d = number of controls without expression of allele or genotype.

Etiologic Fraction (Ef)

The EF indicates the hypothetical genetic component of the disease. The values >0.0–0.99 are of significance. EF was calculated for positive association only where RR > 1 using the following formula.¹⁸

EF = (RR - 1) f / RR, where f = a / a + c

Preventive Fraction (Pf)

The PF indicates the hypothetical protective effect of one specific allele/genotype for the disease. PF was calculated for negative association only where RR < 1 using the following formula.¹⁸

PF = (1 - RR) f / RR (1 - f) + f, where f = a / a + c

Values < 1.0 indicate the protective effect of the allele/genotype against the manifestation of disease.

Results

The demographic and clinical characteristics of the RA patients are summarized in Table 2. Based on clinical history the mean duration of disease was found to be 9 ± 4.5 years. Number of joints involved varied from 2 to 22. Depending on the number joints involved RA patients were classified into two groups: polyarthritis patients (87.74%) with more than 5 joints involved and oligoarthritis (12.26%) with less than 5 joints involved. Morning stiffness duration varied from 10 minutes in mildly affected to several hour in severely affected patients. Number of swollen and tender joints ranged from 0 to 22. Serological results indicated that 82 (77.36%) patients were rheumatoid factor (RF) positive while 24 (22.64%) RF negative.

Table 2.

Demographic and clinical characteristics of RA patients.

No. of patients	106 (F = 85, M = 21)
Age	49 ± 12.5 (26–75 years)
Age of onset	40 ± 10.5 (20–69 years)
Disease duration	9 ± 4.5 (2–34 years)
No. of joints involved	10 (2–22)
Polyarthritis (>5 joints involved)	93
Oligoarthritis (<5 joints involved)	13
Swollen joints count	6 (0–22)
Tender joints count	5 (0–22)
RF positive	82
RF negative	24
RF	210 IU/ml (85–760 IU/ml)
ESR	28 (2–127 mm/h)
C-reactive protein	20 (3–155 mg/l)

Note: Parameters are presented as mean ± standard deviation (range) or number.

The genotypes and alleles frequencies of TNF-α –308 promoter polymorphism in RA patients and control individuals are presented in Table 3. The frequency of allele-A was significantly lower in RA patients as compared to control group (P = 0.005, RR = 0.48, PF = 0.242) on the other hand the frequency of allele-G was higher in RA patients as compared to the controls (P = 0.005, RR = 1.87, and EF = 0.242). The homozygous GG genotype was present in 64.15% of the RA patients and 50% of controls (P = 0.033), while heterozygous GA was found in 33.01% of RA patients against 38.09% of controls (P = 0.492). The homozygous AA genotype was found in 2.83% of RA patients and 11.90% of control samples (P = 0.012). Allele-A containing genotypes (GA and AA) were present in 35.84% of patients and 50% of the healthy controls (P = 0.033). Susceptibility to RA was significant for homozygote for TNF-α 308 G-allele (GG) (P = 0.033; RR = 1.789; EP = 0.261). The predominance of GG genotype among the patients group indicated that the GG genotype was associated with the susceptibility to RA while AA has protective effect on the susceptibility to RA as it was more common in control samples (P = 0.012, RR = 0.25, PF = 0.337). G-Allele (1-allele) of TNF-α seems to be susceptible to RA (P = 0.005, RR = 1.87, and EF = 0.242) whereas A-Allele (2-allele) of TNF-α seems to be resistant to RA in Saudis (P = 0.005, RR = 0.48, PF = 0.242).

Table 3.

Genotype and allele frequencies of TNFα (G-308A) polymorphism in RA patients and matched controls.

Genotype/allele	RA (N = 106)		Control (N = 126)		P-value	RR	EF*/PF
Genotype/allele	N	%	N	%
GG	68	64.15	63	50	0.033^♣	1.79	0.261*
GA	35	33.01	48	38.09	0.492	0.66	0.156
AA	3	2.83	15	11.90	0.012^♣	0.25	0.337
GA and AA	38	35.84	63	50	0.033^♣	0.55	0.223
G-allele	171	80.66	174	69.04	0.005^♣	1.87	0.242*
A-allele	41	19.33	78	30.95	0.005^♣	0.48	0.242

Note: N, number of subjects; ^♣Statistically significant.

Abbreviations: EF, etiological fraction; PF, preventive fraction.

The distribution of genotypes and alleles frequencies of TNF-α –308 promoter polymorphism in relation to duration of morning stiffness, RF positive or RF negative and type of arthritis (polyarthritis and oligoarthritis) is given in Table 4. There was no significant association between duration of morning stiffness, RF positivity and number of joints involved (polyarthritis/oligoarthritis) and distribution of alleles/genotypes of TNF-α –308 polymorphism.

Table 4.

Genotype and allele frequencies of TNFα (G-308A) polymorphism in RA patients in relation to clinical features.

Genotype/allele	Morning stiffness duration				P-value	Rheumatoid factor				P-value	Type of arthritis				P-value
	1-3 hr (N = 81)		0–<1 hr (N = 25)			Positive (N = 82)		Negative (N = 24)			Polyarthritis N = 93		Oligoarthritis N = 13
	N	%	N	%		N	%	N	%		N	%	N	%
GG	50	61.73	18	72	0.47	50	60.97	18	75	0.23	62	66.67	6	46.15	0.21
GA	29	35.80	6	24	0.33	30	36.60	5	20.83	0.21	29	31.18	6	46.15	0.35
AA	2	2.47	1	4	0.55	2	2.43	1	4.17	0.54	2	2.15	1	7.70	0.33
G-allele	129	79.63	42	84	0.54	130	79.27	41	85.42	0.41	153	82.26	18	69.23	0.12
A-allele	33	20.37	8	16	0.54	34	20.73	7	14.58	0.41	33	17.74	8	30.77	0.12

Note: N, number of subjects.

The distributions of genotype and allele frequencies of TNF-β (+252) promoter polymorphism in Saudi patients with RA and controls subjects are summarized in Table 5. The frequency of GG, GA and AA genotypes of TNF–β (+252) showed statistically significant differences between patients and controls. The GG and AA genotypes were significantly over-represented in RA patients as compared to the controls (P = 0.044 and P = 0.0009 respectively) while GA genotype was significantly higher in controls as compared to RA patients (P = 0.0001). These results indicated that GG and AA genotypes at +252 were susceptible to RA (RR = 2.050, EF = 0.254, and RR = 3.523. EF = 0.472 respectively), on the other hand GA was found to be refractory (RR = 0.282, PF = 0.441). Though there were differences in the frequency distribution of allele-A and allele-G of TNF-β (+252) polymorphisms in Saudi RA patients and controls however these differences were not statistically significant (P = 0.457).

Table 5.

Genotype and allele frequencies of TNFβ (G+252A) polymorphism in RA patients and matched controls.

Genotype/allele	RA (N = 106)		Control (N = 126)		P-value	RR	EF*/PF
Genotype/allele	N	%	N	%	P-value	RR	EF*/PF
GG	27	25.47	18	14.28	0.044^♣	2.050	0.254*
GA	47	44.33	93	73.80	0.0001^♣	0.282	0.441
AA	32	30.18	15	11.90	0.0009^♣	3.523	0.472*
GA and AA	79	74.52	108	85.71	0.044^♣	0.487	0.288
G-allele	101	47.64	129	51.19	0.457	0.954	0.089
A-allele	111	52.35	123	48.80	0.457	1.152	0.088*

Note: N, number of subjects; ^♣Statistically significant.

Abbreviations: EF, etiological fraction; PF, preventive fraction.

The distribution of genotypes and alleles frequencies of TNF-β (+252) polymorphism in relation to duration of morning stiffness, RF positive or RF negative and polyarthritis/oligoarthritis is given in Table 6. Analysis of data suggested that there was no significant association between duration of morning stiffness, RF positivity and number of joints involved (polyarthritis/oligoarthritis) and alleles/genotypes frequency of TNF-β (+252) polymorphism.

Table 6.

Genotype and allele frequencies of TNFβ (A+252G) polymorphism in RA patients in relation to clinical features.

Genotype/allele	Morning stiffness duration				P-value	Rheumatoid factor				P-value	Type of arthritis				P-value
	1-3 hr (N = 81)		0–< 1 hr (N = 25)			Positive (N = 82)		Negative (N = 24)			Polyarthritis N = 93		Oligoarthritis N = 13
	N	%	N	%		N	%	N	%		N	%	N	%
GG	18	22.22	9	36	0.19	24	29.27	3	12.50	0.11	22	23.65	5	38.46	0.30
GA	37	45.68	10	40	0.65	36	43.90	11	45.83	0.99	41	44.09	6	46.15	0.99
AA	26	32.10	6	24	0.62	22	26.83	10	41.67	0.20	30	32.26	2	15.39	0.33
G-allele	73	45.06	28	56	0.19	84	51.22	17	35.42	0.07	85	45.70	16	61.54	0.14
A-allele	89	54.94	22	44	0.19	80	48.78	31	64.58	0.07	101	54.30	10	38.46	0.14

Note: N, number of subjects.

The comparison between the frequencies of genotypes of TNF-α (G–308A) promoter polymorphism in Saudi healthy population with the frequencies reported for healthy population of various ethnicities worldwide is presented in Table 7. These results clearly indicated ethnic variations in genotype distribution of TNF-α (–308) promoter polymorphism.

Table 7.

Genotype distribution of TNF-α (–308) promoter polymorphism in different healthy groups.

Population/group studied	Genotype frequencies (%)			Reference
Population/group studied	GG	GA	AA	Reference
Saudis	50.0	38.09	11.90	Present study
American	68.2	29.1	2.7	47
Australian	58.0	39.0	3.0	48
Chilean	83.1	16.3	0.6	49
Chinese	85.6	13.3	1.1	7
Chinese	83.2	15.7	1.1	50
Czech	80.66	19.33	0.0	32
Danish	65.8	30.5	3.7	51
Dutch	56.6	38.6	4.5	52
English	59.6	37.4	3.0	53
Finish	68.8	30.0	1.3	54
French	81.6	17.2	1.2	55
German	67.0	28.0	5.0	56
Iranian	96.7	3.3	0.0	30
Japanese	97.0	3.0	0.0	57
Mexican	91.4	8.6	0.0	26
Spanish	82.4	15.7	1.9	25
Swedish	56.5	40.5	3.0	58
Taiwanese	83.4	15.8	0.8	28
West African	81.6	17.0	1.4	59

Discussion

This is the first study dealing with the TNF-α and TNF-β polymorphism in Saudi population with RA. Our results showing significantly lower frequency of –308A allele and higher frequency of –308G allele in RA patients as compared to healthy controls are similar to the findings reported in various other ethnic groups including Taiwan Chinese,¹⁹ Japanese,²⁰ Swedish,²¹ Turkish,²² Hungarian²³ and Han population of Eastern China.⁷ This study along with other published reports supported the view that –308 A allele of TNF-α may exert a protective influence for the development of RA. Contrary to our findings the reports from Australian Caucasian,²⁴ Spanish,²⁵ Mexicans,²⁶ American Caucasians⁶ and Chilean²⁷ showed significantly higher frequency of Allele-A in RA patients as compared to control group. On the other hand no significant difference in frequency of Allele-A in controls and RA patient was observed in Taiwanese,²⁸ Polish,²⁹ Iranian³⁰ and Turkish populations.³¹ Nemec et al³² found no significant difference in genotype and allelic frequencies of TNF-α (–308) polymorphism in Czech population with and without RA.

The exact reason for such a vast variation in the distribution of alleles and genotypes of TNF-α (–308) polymorphism in RA patients in different ethnic groups is far from clear. These differences may be attributed to the ethnicity related genetic makeup in different populations which is evident from the genotype data of TNF-α (–308) polymorphism published from various ethnic healthy groups worldwide (Table 7). Lee et al³³ also suggested that ethnicity has a significant impact on the genotype distribution of TNF-α (–308) polymorphism in RA patients. RA is considered to be a complex disorder and its onset and severity is influenced by genetic as well as environmental factors. Hence the gene-environment interaction are likely to play a significant role on the outcome of polymorphism association studies on RA patients.

In this study no significant association was found between the TNF-α (–308) polymorphism and clinical features of RA such as number of joints involved, RF positivity and duration of morning stiffness. Similar to our results Ates et al.³⁴ also reported no association between TNF-α (–308) polymorphism and RF positivity and erosive disease of RA in Turkish patients. However, the association of the alleles and genotypes of TNF-α (–308) polymorphism has been reported with severity of RA in American, Mexican and Czech populations.^6,26,32 Khanna et al⁶ found an association between TNF-α (–308) polymorphism and progression of radiographic damage in American patients with early seropositive RA, and suggested that the association might be dependent on genetic variants in linkage disequilibrium with TNF-α (–308) A-allele and DRB1*0301. Rodriguiz-Carreon et al²⁶ also found an association between TNF-α (–308) A-allele and severity of RA in Mexicans but independent of HLA-DR alleles. On the other hand Nemec et al³² found no difference in the distribution of genotypes and alleles frequencies between the Czech RA patients and control group. However, on dividing the RA group according to the radio graphical progression of disease they (loc.cit) noticed significant difference in the distribution of genotypes and suggested that GG genotype of TNF-a (–308) polymorphism is associated with the severity of RA in Czech.³²

Our results for TNF-β (+252) promoter polymorphism indicted that GG and AA genotype were susceptible to RA while GA was refractory. Recently Panoulas¹⁰ also reported that GG genotype of TNF-β (+252) polymorphism occurs more frequently in RA patients as compared to general population. Earlier study from our laboratory showed an association of HLA-DRB1*04 and RA in Saudi patients.³⁵ Thus it may be postulated that GG and AA genotypes of TNF-β together with HLA-DRB1*04 might contribute to the RA susceptibility in Saudi population. Association of TNF-β alleles and HLA alleles with RA has also been reported in Japanese population.¹⁴ These investigators reported that TNF-β * 2 (allele-A) along with HLA-DRB1*0405 contributed to the susceptibility to RA. Genetic variations in the TNF and HLA-DRB1 region have also been reported to affect the response to treatment of early RA.³⁶ In our study there was no significant association between the number of joints involved, RF positivity, duration of morning stiffness in Saudi RA patients and TNF-β (+252) polymorphism similar to TNF-α (–308) polymorphism.

Association of TNF-β polymorphism has also been reported with various other autoimmune disorders including Graves’ disease,³⁷ idiopathic membranous glomerulonephritis, IgA nephropathy, insulin dependent diabetes mellitus,³⁸ myasthenia gravis,³⁹ asthma diathesis,⁴⁰ SLE with nephritis,⁴¹ systemic sclerosis⁴² and plaque psoriasis.⁴³ This study indicates that besides its role in numerous autoimmune diseases TNF-β polymorphism is also involved in the pathogenesis of RA.

The present study suggested a significant association between allele frequency and genotype distribution of TNF-α (–308) and TNF-β (+252) polymorphisms and RA susceptibility in Saudi population. Our results together with other published reports supported an important role of ethnicity in the association of TNF-α and TNF-β polymorphism and RA. It is also concluded that TNF-α (–308) and TNF-β (+252) polymorphisms may work in tandem in the pathogenesis of RA in Saudi population. The results of this study may have prognostic value for future clinical observations of RA patients. Further, TNFα (–308) polymorphism may provide guideline in determining the response to anti-TNF α therapy as patients with GG genotype are better responders to anti-TNFα treatment than those with AA or GA.^44–46

Funding

None.

Disclosures

This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The authors of this paper report no conflict of interest. The authors confirm that they have permission to reproduce any copyrighted material.

References

Gambhir

Lawrence

Aggarwal

Misra

Mandal

S.K.

Naik

Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population.

Rheumatol Int. 2010; 30(9): 1211–7.

Brennan

F.M.

Maini

R.N.

Feldmann

TNF alpha—a pivotal role in rheumatoid arthritis?

Br J Rheumatol. 1992; 31: 293–8.

Feldmann

Brennan

F.M.

Foxwell

B.M.

Mainin

R.N.

The role of TNF alpha and IL-1 in rheumatoid arthritis.

Curr Dir Autoimmun. 2001; 3: 188–99.

Beutler

Cerami

The biology of cachectin/TNF-a primary mediator of the host response.

Annu Rev Immunol. 1989; 7: 625–55.

Nedwin

G.E.

Svedersky

L.P.

Bringman

T.S.

Palladino

M.A.

Jr Goeddel

D.V.

Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

J Immunol. 1985; 135: 2492–7.

Khanna

Park

Gersuk

Gold

R.H.

Nepom

G.T.

Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort.

Arthritis and Rheumatism. 2006; 54: 1105–16.

Chen

Fang

Cai

Duan

Cheng

Tumor necrosis factor alpha –308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China.

Rheumatol Int. 2007; 28: 121–6.

Wilson

A.G.

Symons

J.A.

McDowell

T.L.

McDevitt

H.O.

Duff

G.W.

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Proc Natl Acad Sci U S A. 1997; 94: 3195–99.

Abdallah

A.N.

Cucchi-Mouillot

Biteau

Cassaigne

Haras

Iron

Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe regjection.

Eur J Immunogenet. 1999; 26: 249–55.

10.

Panoulas

V.F.

NIkas

S.N.

Smith

J.P.

Douglas

K.M.

Nightingale

Milionis

H.J.

Lymphotoxin 252A > G polymorphism is common associates with myocardial infarction in patients with rheumatoid arthritis.

Ann Rheum Dis. 2008; 67: 1550–6.

11.

Boraska

Zeggini

Groves

C.J.

Rayner

N.W.

Skrabic

Diakite

(2009) Family-based analysis of tumor necrosis factor and lymphotoxin-alpha tag polymorphism with type 1 diabetes in the population of South Croatia.

Hum Immunol. 2009; 70: 195–9.

12.

Messer

Spengler

Jung

M.C.

Honold

Biomer

Pape

G.R.

Polymorphic structure of the tumor necrosis factor (TNF) locus: an Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production.

J Exp Med. 1991; 173: 209–19.

13.

Abraham

L.J.

French

M.A.H.

Dawkins

R.L.

Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor alpha.

Clin Exp Immunol. 1993; 92: 14–8.

14.

Takeuchi

Nabeta

Hong

G.H.

Kawasugi

Mori

Matsuta

The genetic contribution of the TNFa11 microsatellite allele and the TNFb ± 252*2 allele in Japanese RA.

Clin Exp Rheumatol. 2005; 23: 494–8.

15.

Arnett

F.C.

Edworthy

S.M.

Bloch

D.A.

McShane

D.J.

Fries

J.F.

Cooper

N.S.

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Arthritis Rheum. 1988; 31: 315–24.

16.

Perrey

Turney

Pravica

Howell

W.M.

Hutchinson

I.V.

ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms.

Transplant Immunology. 1999; 7: 127–8.

17.

Schallreuter

K.U.

Levenig

Kuhnl

Loliger

Hohl-Tehari

Berger

Histocompatability antigens in vitiligo: Hamburg study on 102 patients from Northern Germany.

Dermatology. 1993; 187: 186–92.

18.

Savejgaard

Platz

Ryder

L.P.

HLA and disease 1982-A survey.

Immunol Rev. 1982; 70: 193–218.

19.

Yen

J.H.

Chenm

C.J.

Tsai

W.C.

Tumor necrosis factor promoter polymorphism in patients with rheumatoid arthritis in Taiwan.

J Rheumatol. 2001; 28: 1788–92.

20.

Seki

Kamizono

Yamada

Higuchi

Matsumoto

Niiya

Polymorphism in the 5′-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis.

Tissue Antigens. 1999; 54: 194–7.

21.

Cvetkovic

J.T.

Wallberg-Jonsson

Stegmayr

Rantapaa-Dahlqvist

Lefvert

A.K.

Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes.

J Rheumatol. 2002; 29: 212–9.

22.

Ozen

Alikasifoglu

Bakkaloglu

Duzova

Jarosova

Nemcova

Tumor necrosis factor α G → A –238 and G → A –308 polymorphisms in juvenile idiopathic arthritis.

Rheumatology. 2002; 41: 223–7.

23.

Balog

Gal

Gyulai

Zsilak

Mandi

Tumor necrosis factor-alpha and heat-shock protein 70–2 gene polymorphisms in a family with rheumatoid arthritis.

Acta Microbiol Immunol Hung. 2004; 51: 263–9.

24.

Danis

V.A.

Millington

Hyland

Lawford

Huang

Grennan

Increased frequency of the uncommon allele of a tumor necrosis factor alpha polymorphism in rheumatoid arthritis and systemic lupus erythematosus.

Dis Markers. 1995; 12: 127–33.

25.

Vinasco

Beraun

Nieto

Fraile

Mataran

Pareja

Polymorphism at the TNF loci in rheumatoid arthritis.

Tissue Antigen. 1997; 49: 74–8.

26.

Rodriguez-Carreon

A.A.

Zuniga

Hernandez-Pacheco

Rodriguez-Perez

J.M.

Perez-Hernandez

Montes de Oca

J.V.

Tumor necrosis factor-alpha –308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans.

J Autoimmun. 2005; 24: 63–8.

27.

Cuenca

Cuchacovich

Perez

Ferreira

Aguirre

Schiattino

The –308 polymorphism in the tumor necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis.

Rheumatology. 2003; 42: 308–13.

28.

S.F.

Huang

C.M.

M.C.

J.Y.

Tsai

F.J.

Lack of association of tumor necrosis factor alpha gene polymorphism in patients with rheumatoid arthritis in central Taiwan.

Rheumatol Int. 2003; 23: 151–3.

29.

Pawlik

Florczak

Ostanek

Brzosko

Szklarz

B.G.

TNF-alpha –308 promoter polymorphism in patients with rheumatoid arthritis.

Scand J Rheumatol. 2005; 34: 22–6.

30.

Rezaieyazdi

Afshari

J.T.

Sandooghi

Mohajer

Tumor necrosis factor α –308 promoter polymorphism in patients with rheumatoid arthritis.

Rheumatol Int. 2007; 28: 189–91.

31.

Ates

Hatemi

Hamuryudan

Topal-Sarikaya

Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients.

Clin Rheumatol. 2008; 27: 1243–8.

32.

Nemec

Pavkova-Goldbergova

Stouracova

Vasku

Soucek

Gatterova

Polymorphism in the tumor necrosis factor-α gene promoter is associated with severity of rheumatoid arthritis in the Czech population.

Clin Rheumatol. 2008; 27: 59–65.

33.

Lee

Y.H.

J.D.

Song

G.G.

Tumor necrosis factor-α promoter –308A/G polymorphism and rheumatoid arthritis susceptibility: a meta-analysis.

J Rheumatol. 2007; 34: 43–9.

34.

Ates

Hatem

Hamuryudan

Tpal-Sarikaya

Tumor necrosis factor – alpha and interleukin-10 gene promoter polymorphism in Turkish rheumatoid arthritis patients.

Clin Rheumatol. 2008; 27: 1243–8.

35.

Al-Swailem

Al-Rayes

Sobki

Arfin

Tariq

HLA-DRB1 association in Saudi rheumatoid arthritis patients.

Rheumatol Int. 2006; 26: 1019–24.

36.

Criswell

L.A.

Lum

R.F.

Turner

K.N.

Woehl

Zhu

Wang

The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.

Arthritis Rheum. 2004; 50: 2750–6.

37.

Kula

Jurecka-Tuleja

Gubala

Krawczyk

Szpak

Jarzab

Association of polymorphism of LT alpha and TNF genes with Grave's disease.

Folia Histochem Cytobiol. 2001; 39: 77–8.

38.

Medcraft

Hitman

G.A.

Sachs

J.A.

Whichelow

C.E.

Raafat

Moore

R.H.

Autoimmune renal disease and tumor necrosis factor beta gene polymorphism.

Clin Nephrol. 1993; 40: 63–8.

39.

Zelano

Lino

M.M.

Evoli

Settesoldi

Batocchi

A.P.

Torrente

Tumor necrosis factor beta gene polymorphisms in myasthenia gravis.

Eur J Immunogenet. 1998; 25: 403–8.

40.

Albuquerque

R.V.

Hayden

C.M.

Palmer

L.J.

Laing

I.A.

Rye

P.J.

Gibson

N.A.

Association of polymorphisms within the tumor necrosis factor (TNF) genes and childhood asthma.

Clin Exp Allergy. 1998; 28: 578–84.

41.

L.Y.

Cheng

H.H.

Sung

P.K.

Tai

M.H.

Yeh

J.J.

Chen

Tumor necrosis factor-beta +252A polymorphism is associated with systemic lupus erythematosus in Taiwan.

J Formos Med Assoc. 2005; 104: 563–70.

42.

Pandey

J.P.

Takeuchi

TNF-α and TNF-β gene polymorphisms in systemic sclerosis – a possible link to insulin-dependent diabetes mellitus.

Hum Immunol. 1999; 60: 1128–30.

43.

Vasku

Izakovicova Holla

Tschoplova

Kankova

Benakova

Polymorphisms in inflammation genes (angiotensinogen, TAP1 and TNF-beta) in psoriasis.

Arch Dermatol Res. 2000; 292: 531–4.

44.

Mugnier

Balandraud

Darque

Roudier

Reviron

Polymorphism at position –308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis.

Arthritis and Rheum. 2003; 48: 1849–52.

45.

Guis

Balandraud

Bouvenot

Auger

Toussirot

Wendling

(2007) Influence of –308A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.

Arthritis Rheum. 2007; 57: 1426–30.

46.

Seitz

Wirthmuller

Moller

Villiger

P.M.

The –308 tumor necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients.

Rheumatology. 2007; 46: 93–6.

47.

Wingerchuk

Liu

Sobell

Sommer

Weinshenker

B.G.

A population-based case-control study of the tumor necrosis factor alpha –308 polymorphism in multiple sclerosis.

Neurology. 1997; 49: 626–8.

48.

Milner

C.R.

Craig

J.E.

Hussey

N.D.

Norman

R.J.

No association between the –308 polymorphism in the tumor necrosis factor α (TNF-α) promoter region and polycystic ovaries.

Mol Hum Reprod. 1999; 5: 5–9.

49.

Cuenca

Perez

Aguirre

Schiattino

Aguillon

J.C.

Genetic polymorphism at position –308 in the promoter region of the tumor necrosis factor (TNF): Implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population.

Biol Res. 2001; 34: 237–41.

50.

Lee

S.C.

Y.B.

Thomas

G.N.

Lee

Z.S.K.

Tomlinson

Cockram

C.S.

Tumor necrosis factor alpha gene G–308A polymorphism in the metabolic syndrome.

Metabolism. 2000; 49: 1021–4.

51.

Rasmussen

S.K.

Urhammer

S.A.

Jensen

J.N.

Hansen

Borch-Johnsen

Pedersen

The –238 and –308 G >A polymorphisms of the tumor necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians.

J Clin Endocrinol Metab. 2000; 85: 1731–4.

52.

Brinkman

B.M.

Huizinga

T.W.

Kurban

S.S.

van der Velde

E.A.

Schreuder

G.M.

Hazes

J.M.

Tumor necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease?

Br J Rheumatol. 1997; 36: 516–21.

53.

Keatings

V.M.

Cave

S.J.

Henry

M.J.

Morgan

O'Connor

C.M.

Fitzgeral

M.X.

A polymorphism in the tumor necrosis factor-α gene promoter region may predispose to a poor prognosis in COPD.

Chest. 2000; 118: 971–5.

54.

Maury

C.P.

Liljestrom

Laiho

Tiitinen

Kaarela

Hurme

Tumor necrosis factor alpha, its soluble receptor I, and –308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.

Arthritis Rheum. 2003; 48: 3068–76.

55.

Mira

J.P.

Cariou

Grall

Delclaux

Losser

M.R.

Heshmati

Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality.

JAMA. 1999; 282: 561–8.

56.

Hohler

Kruger

Gerken

Schneider

P.M.

Meyer Zum Buschenefelde

K.H.

Rittner

A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection.

Clin Exp Immunol. 1998; 11: 579–82.

57.

Ishii

Hirose

Saito

Nishikai

Maruyama

Saruta

Tumor necrosis factor alpha gene G-308A polymorphism, insulin resistance, and fasting plasma glucose in young, older, and diabetic Japanese men.

Metabolism. 2000; 49: 1616–8.

58.

Rosmond

Chagnon

Bouchard

Bjorntorp

G-308 A polymorphism of the tumor necrosis factor alpha gene promoter and salivary cortisol secretion.

J Clin Endocrinol Metab. 2001; 86: 2178–80.

59.

Conway

D.J.

Holland

M.J.

Bailey

R.L.

Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid.

Infect Immun. 1997; 65: 1003–6.